| Images |
Sources |
Experiment + Assay |
Phenotypes |
Human Diseases |
|
Fig. 5 A , Sup Fig. 5 A
Maerker M et al. (2021)
|
Xla Wt + bicc1 MO + dand5 MO
NF20 (in situ hybridization)
|
|
|
|
|
Fig. 5 B C
Maerker M et al. (2021)
|
Xla Wt + bicc1 MO + dand5 MO
NF20 (in situ hybridization)
|
|
|
|
|
Fig. 5 C
Maerker M et al. (2021)
|
Xla Wt + bicc1 MO + dand5 MO
NF20 (in situ hybridization)
|
|
|
|
|
Fig. 5 A, Sup Fig. 5 A
Maerker M et al. (2021)
|
Xla Wt + bicc1 MO + dand5 MO
NF32 (in situ hybridization)
|
|
|
|
|
Fig. 5 D, Sup. Fig. 5 B
Maerker M et al. (2021)
|
Xla Wt + bicc1 MO + dand5 MO
NF32 (in situ hybridization)
|
|
|
|
|
Fig. 5 D, Sup Fig. 5 B
Maerker M et al. (2021)
|
Xla Wt + bicc1 MO + dand5 MO
NF32 (in situ hybridization)
|
|
|
|
Fig. 2 F, Sup. Fig. 2 A
Maerker M et al. (2021)
|
Xla Wt + dand5 MO
NF16 (in situ hybridization)
|
|
|
|
|
Fig. 2 F
Maerker M et al. (2021)
|
Xla Wt + dand5 MO
NF16 (in situ hybridization)
|
|
|
|
|
Fig. 2 D E
Maerker M et al. (2021)
|
Xla Wt + dand5 MO
NF20 (in situ hybridization)
|
|
|
|
|
Fig. 2 D E
Maerker M et al. (2021)
|
Xla Wt + dand5 MO
NF20 (in situ hybridization)
|
|
|